Italia markets open in 2 hours 52 minutes

Orion Oyj (0M2N.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
33,35-0,15 (-0,45%)
Alla chiusura: 06:03PM BST

Orion Oyj

Orionintie 1A
Espoo 02200
Finland
358 10 4261
https://www.orion.fi

Settore/i
Settore
Impiegati a tempo pieno3.632

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Liisa HurmePresident, CEO & Chairman of Executive Management Board770,28kN/D1967
Mr. Jari Karlson M.Sc., M.Sc. (Econ.)CFO & Member of the Executive Management BoardN/DN/D1961
Mr. Olli Huotari Ll.M.Senior VP of Corporate Functions, General Counsel, Secretary & Member of Executive Management BoardN/DN/D1966
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. BoardN/DN/D1966
Prof. Outi Vaarala M.D., Ph.D.Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. BoardN/DN/D1962
Mr. Juhani KankaanpaaSenior VP of Global Operations & Member of Executive Management BoardN/DN/DN/D
Mr. Niclas Lindstedt EMBA, M.Sc.Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. BoardN/DN/DN/D
Mr. Hao Pan M.Sc.Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. BoardN/DN/D1971
Ms. Julia Irene MachareySenior Vice President of People & Culture and Member of Management BoardN/DN/D1977
Mr. Rene Lindell M.Sc., Ph.D.Member of Group Executive Management BoardN/DN/D1976
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Governance aziendale

L'ISS Governance QualityScore di Orion Oyj al 1 aprile 2024 è 2. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 1; diritti degli azionisti: 10; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.